Trial Profile
Phase 2 trial of ponatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure or intolerance of prior therapy with imatinib (POETIG trial – POnatinib after rEsisTance to Imatinib in GIST)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms POETIG
- 02 May 2023 Status changed from recruiting to completed.
- 31 May 2020 Interim results (n=39; data cutoff: 31 Jan 2020) of safety data of all cohorts and first efficacy data of last line cohort presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 14 Feb 2017 New trial record